Anatara Lifesciences Ltd · ASX:ANR
Anatara Lifesciences — Shareholder Meeting (November 2025)
9 slides from Anatara Lifesciences's shareholder meeting presentation, Nov 20, 2025
Slide 1: Company Update – AGM 20 November 2025
Company Update A N A T A R A L I F E S C I E N C E S L T D A G M 2 0 TH N O V E M B E R 2 0 2 5
Slide 2: Disclaimer
ANATARA LIFESCIENCES Disclaimer The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 1
Slide 3: Weight Management and Anti-Obesity Project
Weight Management and Anti-Obesity Project Significant Opportunity Unmet need and extremely large market for a safe, easy to use, cost effective weight loss product • There is a significant opportunity in the market to address a critical gap in the management of long-term weight, including preventin
Slide 4: Preliminary results from Anti-Obesity Project proof of concept mice studies
Anatara’s preliminary results from Anti-Obesity Project proof of concept mice studies of 3 compounds, with AO B and AO C of particular interest.
Slide 5: Obesity - the new pandemic
Obesity - the new pandemic Quick Facts • In North America, more than 1 in 3 adults get the minimum recommended physical activity each week. In Australia this is 1 in 4. • Countries with high obesity rates correlate with high sugar consumption (>50 kg per person per annum). • 5.6% of Australians and
Slide 6: Risks associated with Obesity
Risks associated Co-morbidities associated with Obesity with Obesity 1. Increased Mortality Risk 1. Hypertension 2. Cardiovascular Risks 2. Coronary Artery Disease 3. Metabolic Risks 3. Type 2 Diabetes Mellitus 4. Respiratory Risks 4. Dyslipidaemia 5. Cancer Risks 5. Obstructive Sleep Apnoea 6. Musc
Slide 7: GaRP Bromelain
GaRP Bromelain Reduces pro-inflammatory cytokines & serotonin; promotes healing via mucin ONE PRODUCT, MULTIPLE BENEFITS genes;reduces attachment some bacteria. Patent Protected Scientifically designed for the relief and management of background IBS symptoms and the rejuvenation of GIT ( Gastrointes
Slide 8: Project updates summary
Company update • Anti-Obesity Project –encouraging preliminary results from the proof of concept pre-clinical studies on compounds suitable to develop an oral medication to assist weight reduction and sustain weight control, in conjunction with other contemporary treatments and approaches. The forma
Slide 9: Contact Us
David Brookes Executive Chair Contact Us info@anatara.com Image Image Image ANATARA LIFESCIENCES LTD www.anataralifesciences.com
Anatara Lifesciences — Shareholder Meeting (November 2025) on 6ix